These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

391 related articles for article (PubMed ID: 35241844)

  • 1. Immune response to SARS-CoV-2 after a booster of mRNA-1273: an open-label phase 2 trial.
    Chu L; Vrbicky K; Montefiori D; Huang W; Nestorova B; Chang Y; Carfi A; Edwards DK; Oestreicher J; Legault H; Dutko FJ; Girard B; Pajon R; Miller JM; Das R; Leav B; McPhee R
    Nat Med; 2022 May; 28(5):1042-1049. PubMed ID: 35241844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and immunogenicity against ancestral, Delta and Omicron virus variants following a booster dose of an inactivated whole-virus COVID-19 vaccine (VLA2001): Interim analysis of an open-label extension of the randomized, controlled, phase 3 COV-COMPARE trial.
    Taucher C; Lazarus R; Dellago H; Maurer G; Weisova P; Corbic-Ramljak I; Dubischar K; Lilja A; Eder-Lingelbach S; Hochreiter R; Jaramillo JC; Junker H; Krammer M; Pusic P; Querton B; Larcher-Senn J; Hoffmann M; Pöhlmann S; Finn A;
    J Infect; 2023 Sep; 87(3):242-254. PubMed ID: 37406777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trial.
    Chalkias S; Eder F; Essink B; Khetan S; Nestorova B; Feng J; Chen X; Chang Y; Zhou H; Montefiori D; Edwards DK; Girard B; Pajon R; Dutko FJ; Leav B; Walsh SR; Baden LR; Miller JM; Das R
    Nat Med; 2022 Nov; 28(11):2388-2397. PubMed ID: 36202997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interim safety and immunogenicity of COVID-19 omicron BA.1 variant-containing vaccine in children in the USA: an open-label non-randomised phase 3 trial.
    Dixit A; Bennett R; Ali K; Griffin C; Clifford RA; Turner M; Poston R; Hautzinger K; Yeakey A; Girard B; Zhou W; Deng W; Zhou H; Schnyder Ghamloush S; Kuter BJ; Slobod K; Miller JM; Priddy F; Das R;
    Lancet Infect Dis; 2024 Jul; 24(7):687-697. PubMed ID: 38518789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and immunogenicity of COReNAPCIN, a SARS-CoV-2 mRNA vaccine, as a fourth heterologous booster in healthy Iranian adults: A double-blind, randomized, placebo-controlled, phase 1 clinical trial with a six-month follow-up.
    Salehi M; Alavi Darazam I; Nematollahi A; Alimohammadi M; Pouya S; Alimohammadi R; Khajavirad N; Porgoo M; Sedghi M; Mahdi Sepahi M; Azimi M; Hosseini H; Mahmoud Hashemi S; Dehghanizadeh S; Khoddami V
    Int Immunopharmacol; 2024 Jun; 134():112192. PubMed ID: 38761778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and immunogenicity of a high-dose quadrivalent influenza vaccine administered concomitantly with a third dose of the mRNA-1273 SARS-CoV-2 vaccine in adults aged ≥65 years: a phase 2, randomised, open-label study.
    Izikson R; Brune D; Bolduc JS; Bourron P; Fournier M; Moore TM; Pandey A; Perez L; Sater N; Shrestha A; Wague S; Samson SI
    Lancet Respir Med; 2022 Apr; 10(4):392-402. PubMed ID: 35114141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and Immunogenicity of a 100 μg mRNA-1273 Vaccine Booster for Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2).
    Chalkias S; Schwartz H; Nestorova B; Feng J; Chang Y; Zhou H; Dutko FJ; Edwards DK; Montefiori D; Pajon R; Leav B; Miller JM; Das R
    medRxiv; 2022 Mar; ():. PubMed ID: 35291289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity and safety of a single booster dose of NVX-CoV2373 (TAK-019) in healthy Japanese adults who had previously received a primary series of COVID-19 mRNA vaccine: Primary analysis report of a phase 3 open-label trial.
    Kuriyama K; Murakami K; Masuda T; Sugiura K; Sakui S; Schuring RP; Mori M
    Vaccine; 2023 Jun; 41(25):3763-3771. PubMed ID: 37198021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity and safety of a second heterologous booster dose of NVX-CoV2373 (TAK-019) in healthy Japanese adults who had previously received a primary series of COVID-19 mRNA vaccine: Interim analysis report of a phase 3 open-label trial.
    Kuriyama K; Murakami K; Sugiura K; Sakui S; Schuring RP; Mori M
    Vaccine; 2024 Jan; 42(3):662-670. PubMed ID: 38129286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Three-month antibody persistence of a bivalent Omicron-containing booster vaccine against COVID-19.
    Chalkias S; Harper C; Vrbicky K; Walsh SR; Essink B; Brosz A; McGhee N; Tomassini JE; Chen X; Ying Chang ; Sutherland A; Montefiori DC; Girard B; Edwards DK; Jing Feng ; Zhou H; Baden LR; Miller JM; Das R
    Nat Commun; 2023 Aug; 14(1):5125. PubMed ID: 37612300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis.
    Choi A; Koch M; Wu K; Chu L; Ma L; Hill A; Nunna N; Huang W; Oestreicher J; Colpitts T; Bennett H; Legault H; Paila Y; Nestorova B; Ding B; Montefiori D; Pajon R; Miller JM; Leav B; Carfi A; McPhee R; Edwards DK
    Nat Med; 2021 Nov; 27(11):2025-2031. PubMed ID: 34526698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity and safety of single booster dose of KD-414 inactivated COVID-19 vaccine in adults: An open-label, single-center, non-randomized, controlled study in Japan.
    Terada-Hirashima J; Takamatsu Y; Shimizu Y; Uemura Y; Takeuchi JS; Tomita N; Matsuda K; Maeda K; Yamamoto S; Fukunaga A; Ohmagari N; Mikami A; Sonoda K; Ujiie M; Mitsuya H; Sugiura W
    Hum Vaccin Immunother; 2023 Dec; 19(1):2193074. PubMed ID: 37052247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Bivalent Omicron-Containing Booster Vaccine against Covid-19.
    Chalkias S; Harper C; Vrbicky K; Walsh SR; Essink B; Brosz A; McGhee N; Tomassini JE; Chen X; Chang Y; Sutherland A; Montefiori DC; Girard B; Edwards DK; Feng J; Zhou H; Baden LR; Miller JM; Das R
    N Engl J Med; 2022 Oct; 387(14):1279-1291. PubMed ID: 36112399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and immunogenicity of a bivalent SARS-CoV-2 protein booster vaccine, SCTV01C, in adults previously vaccinated with mRNA vaccine: a randomized, double-blind, placebo-controlled phase 1/2 clinical trial.
    Hannawi S; Saifeldin L; Abuquta A; Alamadi A; Mahmoud SA; Hassan A; Liu D; Yan L; Xie L
    EBioMedicine; 2023 Jan; 87():104386. PubMed ID: 36470077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial.
    Chen GL; Li XF; Dai XH; Li N; Cheng ML; Huang Z; Shen J; Ge YH; Shen ZW; Deng YQ; Yang SY; Zhao H; Zhang NN; Zhang YF; Wei L; Wu KQ; Zhu MF; Peng CG; Jiang Q; Cao SC; Li YH; Zhao DH; Wu XH; Ni L; Shen HH; Dong C; Ying B; Sheng GP; Qin CF; Gao HN; Li LJ
    Lancet Microbe; 2022 Mar; 3(3):e193-e202. PubMed ID: 35098177
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intradermal delivery of the third dose of the mRNA-1273 SARS-CoV-2 vaccine: safety and immunogenicity of a fractional booster dose.
    Roozen GVT; Prins MLM; Prins C; Janse JJ; de Gruyter HLM; Pothast CR; Huisman W; Koopman JPR; Lamers OAC; Kuijer M; Myeni SK; van Binnendijk RS; Hartog GD; Heemskerk MHM; Jochems SP; Feltkamp MCW; Kikkert M; Rosendaal FR; Roestenberg M; Visser LG; Roukens AHE
    Clin Microbiol Infect; 2024 Jul; 30(7):930-936. PubMed ID: 38552793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Phase 3, randomized, non-inferiority study of a heterologous booster dose of SARS CoV-2 recombinant spike protein vaccine in adults.
    Kulkarni PS; Gunale B; Kohli S; Lalwani S; Tripathy S; Kar S; Raut S; Kulkarni P; Apte A; Bavdekar A; Bhalla HL; Plested JS; Cloney-Clark S; Zhu M; Kalkeri R; Pryor M; Hamilton S; Thakar M; Sannidhi RS; Baranwal P; Bhamare C; Dharmadhikari A; Gupta M; Poonawalla CS; Shaligram U; Kapse D;
    Sci Rep; 2023 Oct; 13(1):16579. PubMed ID: 37789040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and immunogenicity of primary vaccination with a SARS-CoV-2 mRNA vaccine (SYS6006) in Chinese participants aged 18 years or more: Two randomized, observer-blinded, placebo-controlled and dose-escalation phase 1 clinical trials.
    Chen GL; Qiu YZ; Wu KQ; Wu Y; Wang YH; Zou YY; Peng CG; Zhao J; Su C; Ma JH; Ni SN; Wang X; Jin TH; Jiang Q; Guo T; Xu Y; Huang CC; Zhang Q; Liu KL; Ji L; Yang HY; Li CL; Su YW; Lu X; Li LJ
    Hum Vaccin Immunother; 2023 Dec; 19(3):2285089. PubMed ID: 38111106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity and safety of a fourth homologous dose of NVX-CoV2373.
    Alves K; Plested JS; Galbiati S; Chau G; Cloney-Clark S; Zhu M; Kalkeri R; Patel N; Smith K; Marcheschi A; Pfeiffer S; McFall H; Smith G; Glenn GM; Dubovsky F; Mallory RM;
    Vaccine; 2023 Jun; 41(29):4280-4286. PubMed ID: 37271706
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity and safety of a SARS-CoV-2 mRNA vaccine (SYS6006) in healthy Chinese participants: A randomized, observer-blinded, placebo-controlled phase 2 clinical trial.
    Jin F; Qiu Y; Wu Z; Wang YH; Cai C; Fu L; Jiao W; Wang H; Gao M; Su C; Ma JH; Xu Y; Huang CC; Zhang Q; Ni S; Zhao M; Guo L; Ji L; Yang H; Zhao Y; Li C; Lu X; Su YW; Li Q
    Vaccine; 2024 Mar; 42(7):1561-1570. PubMed ID: 38365485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.